Medicare AdvantageCoverageMedium impact
MA07.056f, Photodynamic Therapy (PDT) Using Levulan® Kerastick® or Ameluz® (Aminolevulinic Acid HCl [ALA])
Independence Blue Cross·Dermatology·Pharmacy
Effective date
Jan 1, 2026
We identified it
Jun 19, 2026
Summary
Medicare Advantage policy MA07.056f for Photodynamic Therapy (PDT) using Levulan® Kerastick® or Ameluz® has been updated with new coverage guidelines effective January 1, 2026. This affects billing for PDT treatments using these specific aminolevulinic acid formulations.
Action Required
By January 1, 2026: Billing team must review the complete MA07.056f policy at the IBX website to understand new coverage criteria for PDT using Levulan® Kerastick® or Ameluz®. Update prior authorization processes and billing procedures for dermatology PDT treatments according to the new Medicare Advantage guidelines.